| Use of terfenadine and contraindicated drugs. | |
| | |
MedLine Citation:
|
PMID: 8614120 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To assess changes in concurrent use of products containing terfenadine and contraindicated macrolide antibiotics (erythromycin, clarithromycin, troleandomycin) and imidazole antifungals (ketoconazole, itraconazole) following reports of serious drug-drug interactions and changes in product labeling. DESIGN: Retrospective review of computerized pharmacy claims. SETTING: A large health insurer in New England. PATIENTS: Health plan members with 1 or more paid pharmacy claims for products containing terfenadine between January 1990 and June 1994. MAIN OUTCOME MEASURES: Among persons with paid claims for terfenadine in any given month, percentage with a prescription for any contraindicated drug that alternatively was dispensed on the same day as ("same-day dispensing") or had therapy days that overlapped those of ("overlapping use") a prescription for terfenadine. RESULTS: Concurrent use of terfenadine and contraindicated drugs declined over the study period. The rate of same-day dispensing declined by 84% from an average of 2.5 per 100 persons receiving terfenadine in 1990 to 0.4 per 100 persons during the first 6 months of 1994, while the rate of overlapping use declined by 57% (from 5.4 to 2.3 per 100 persons). Most cases involved erythromycin. CONCLUSIONS: Despite substantial declines following reports of serious drug-drug interactions and changes in product labeling, concurrent use of terfenadine and contraindicated macrolide antibiotics and imidazole antifungals continues to occur. |
| | |
Authors:
|
D Thompson; G Oster |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: JAMA : the journal of the American Medical Association Volume: 275 ISSN: 0098-7484 ISO Abbreviation: JAMA Publication Date: 1996 May |
Date Detail:
|
Created Date: 1996-05-31 Completed Date: 1996-05-31 Revised Date: 2010-03-24 |
Medline Journal Info:
|
Nlm Unique ID: 7501160 Medline TA: JAMA Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1339-41 Citation Subset: AIM; IM |
Affiliation:
|
Policy Analysis Inc, Brookline, Mass, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Bacterial Agents
/
contraindications*,
therapeutic use* Antifungal Agents / contraindications*, therapeutic use* Clarithromycin / contraindications, therapeutic use Drug Interactions Drug Utilization Erythromycin / contraindications, therapeutic use Histamine H1 Antagonists / contraindications*, therapeutic use* Humans Itraconazole / contraindications, therapeutic use Ketoconazole / contraindications, therapeutic use Pharmaceutical Services Product Labeling Retrospective Studies Terfenadine / contraindications*, therapeutic use* Troleandomycin / contraindications, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents; 0/Antifungal Agents; 0/Histamine H1 Antagonists; 114-07-8/Erythromycin; 2751-09-9/Troleandomycin; 50679-08-8/Terfenadine; 65277-42-1/Ketoconazole; 81103-11-9/Clarithromycin; 84625-61-6/Itraconazole |
| Comments/Corrections | |
Comment In:
|
JAMA. 1996 Sep 25;276(12):953
[PMID:
8805726
]
JAMA. 1996 Sep 25;276(12):953 [PMID: 8805725 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies.
Next Document: A meta-analytic evaluation of the polymerase chain reaction for the diagnosis of HIV infection in in...